Skip to content

Management of Pre-Menstrual Symptoms with the help of Brahmi churna and Jatamansi churna capsule

Comparative Clinical Study To Evaluate The Efficacy Of Brahmi Churna Capsule And Jatamansi Churna Capsule In Pre-Menstrual Syndrome.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055516
Enrollment
60
Registered
2023-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E35- Disorders of endocrine glands in diseases classified elsewhere

Interventions

None listed

Sponsors

Parul Institute Of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18 yrs to 40 yrs of age irrespective of socio economic status and in good medical health 2. Female subjects having regular menstrual cycle with cycle length of 21-35 days. 3. Having a minimum PMTS score >10 and VAS score >1 4. Symptoms should appear at definite time in luteal phase of the cycle. 5. The subject should be symptomatic for a period of last 3 or more than 3 months. 6. Symptoms should not persist beyond the 5th day of menstrual cycle. 7. The subjects who are ready to follow the treatment protocol and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Women aged below 18 and above 40 years 2. Subject suffering from other acute or chronic psychiatric illness. 3. Those with symptoms existing less than 3 menstrual cycles. 4. Subjects having diabetes mellitus, hypertension, thyroid, PCOS, DUB 5. Subjects suffering from organic brain diseases. 6. Subjects under hormonal and psychiatric treatment. 7. Subjects taking oral contraceptive pills. 8. Subjects with premenstrual dysphoric disorder

Design outcomes

Primary

MeasureTime frame
To subside Pre-Menstrual SymptomsTimepoint: 30 days

Secondary

MeasureTime frame
Improvement in quality of life.Timepoint: The outcomes will be measured after screening at Base Line BT after 1 month & at the end of 2 months AT Assessment of clinical parameters will also be done at the end of the 3rd month after 1 month of medicine free period

Countries

India

Contacts

Public ContactDr.Vrushalee Dodke

Parul Institute Of Ayurveda

vrushaleedodke@gmail.com09823088621

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026